FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Education to Targeted Exposure Analysis
If you're experiencing persistent nausea, bloating, or abdominal pain while using Ozempic, you may be concerned about gastroparesis. This condition, characterized by delayed stomach emptying, has been reported in association with GLP-1 receptor agonists. Building on a long tradition of patient safety monitoring, this guide explains the key follow-up tests and exams recommended for individuals on Ozempic who develop symptoms of gastroparesis.
Ozempic and Gastroparesis: A Mechanistic Link
Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action involves slowing gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of a mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis often includes persistent nausea and vomiting, which can be severe enough to cause dehydration, electrolyte imbalances, and malnutrition. Diagnosis typically involves gastric emptying scintigraphy, where a radiolabeled meal is tracked over time, or other motility studies. The link between Ozempic and gastroparesis is grounded in the drug's known effect on gastric motility. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can, in susceptible individuals, progress to a state of functional gastric stasis resembling gastroparesis.
Clinical Evidence and Labeling Gaps
While the prescribing information for Ozempic does not explicitly list gastroparesis as a labeled adverse reaction, it documents a range of gastrointestinal adverse events. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, in a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Other gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which aligns with the mechanistic pathway of delayed gastric emptying. However, the labeling does not specifically warn of gastroparesis as a distinct adverse event, raising questions about the adequacy of warnings. The warnings section of the label addresses hypersensitivity reactions, including anaphylaxis and angioedema, but does not mention gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be significant for patients who develop severe, persistent gastrointestinal symptoms that meet the clinical criteria for gastroparesis.
Statute of Limitations in California for Ozempic-Related Gastroparesis Claims
For affected patients in California, settlement-related considerations hinge on the statute of limitations, which generally requires filing a lawsuit within a certain period from the date of injury or discovery of the harm. In California, the statute of limitations for personal injury claims is typically two years from the date of injury, but this can be extended under the discovery rule if the injury was not immediately apparent. For gastroparesis linked to Ozempic, the timeline between exposure and documented harm is critical. Symptoms often emerge during dose escalation, as noted in clinical trials, but the progression to diagnosed gastroparesis may take months. Patients who began Ozempic and later developed persistent nausea, vomiting, and abdominal pain should document the onset of symptoms relative to drug initiation. Medical records confirming a diagnosis of gastroparesis via gastric emptying studies, along with a temporal relationship to Ozempic use, are essential for any potential claim. The adequacy of warnings is a central issue in settlement discussions. If the manufacturer failed to adequately warn about the risk of gastroparesis, patients may argue that they were not fully informed of the potential harm. The current label lists gastrointestinal adverse reactions but does not specifically warn of gastroparesis, which could be considered a gap in risk communication. Settlement-related considerations for affected patients include the strength of the causal link, the severity of the injury, and the timing of the claim. Given the mechanistic plausibility and the documented gastrointestinal effects, patients with confirmed gastroparesis after Ozempic use may have a basis for legal action. However, the statute of limitations in California requires prompt action. Patients should consult with a legal professional to assess their individual circumstances, including the date of diagnosis and the date they first suspected a link to Ozempic. In summary, the evidence supports a mechanistic link between Ozempic and gastroparesis through delayed gastric emptying, though the label does not explicitly warn of this condition. The statute of limitations in California for such claims is generally two years, making timely evaluation essential for affected patients.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in California?
In California, the statute of limitations for personal injury claims, including those related to Ozempic-induced gastroparesis, is generally two years from the date of injury or from the date the injury was discovered or should have been discovered. The discovery rule may extend this period if the harm was not immediately apparent. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.
Does Ozempic's label warn about gastroparesis?
No, the prescribing information for Ozempic does not explicitly list gastroparesis as a labeled adverse reaction. It documents gastrointestinal adverse events such as nausea, vomiting, and diarrhea, but does not specifically warn of gastroparesis. This omission may be relevant in legal claims regarding the adequacy of warnings. For detailed label information, refer to the DailyMed entry (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.